CHIMERIC THERAPEUTICS LIMITED (CHM)
Latest AI Signal: BUY
Status: EXPIRED
Days Old: 30
Confidence: 35%
Date: 21-04-2026
Price: $0.002
Last Price: $0.130
Post-Signal Peak Price: $0.210
Latest CHIMERIC THERAPEUTICS LIMITED(CHM) News
21 Jun 2022, 10:00 PM
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional Investors
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will h
16 Nov 2021, 01:00 AM
30 Minute presenting time slots from 9am to 1pm EST November 16, 2021 Presentation times and links distributed for all presenting companies Investors will be provided time after presentation to ask questions Welcome all institutional and retail investors
NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) --
BUY Confidence Low
AI Confidence - 35 % model confidence
Business Overview
Chimeric Therapeutics Limited is an Australian biotechnology company focused on developing innovative CAR T-cell therapies targeting solid tumors. Positioned in the emerging immuno-oncology sector, the company aims to address significant unmet medical needs with its proprietary chimeric antigen receptor technology, targeting cancers with high mortality rates and limited treatment options.
Financial Analysis
| Cash Flow | Weak |
| Debt | Low |
| Profitability | Weak |
| Revenue Trend | Unknown |
Technical Analysis
| Trend | Bullish |
| Momentum | Moderate |
| RSI Signal | Neutral |
| Support Level | $ 0.0018 |
| Resistance Level | $ 0.0025 |
Valuation
Valuation - Undervalued
The stock trades at a very low price reflecting early-stage development risk, but with significant upside potential if clinical milestones are achieved.
Catalysts
• Upcoming clinical trial results or regulatory updates
• Strategic partnerships or licensing agreements
• Positive preclinical data releases or technological advancements
Recommendation
Action - Buy
Timeframe - Medium Term
Chimeric Therapeutics presents a compelling speculative opportunity in the CAR T-cell therapy space with promising technology and upcoming catalysts. While financial and clinical risks remain high, the current valuation offers attractive upside for investors with a medium-term horizon.